Document is current
Any future updates will be listed below
-
Authors
Nakaya, Nanami https://orcid.org/0009-0004-3711-2118
Yamasato, Ami https://orcid.org/0009-0000-2450-0235
Kondo, Mayu https://orcid.org/0009-0000-0164-3540
Okino, Shigeki https://orcid.org/0009-0003-3183-1763
Kitano, Atsuko https://orcid.org/0000-0001-8881-3329
Tsuda, Banri
Tokuhara, Makoto https://orcid.org/0009-0001-8668-1219
Yamamoto, Kenji https://orcid.org/0000-0002-0031-9068
-
Funding
Funding for this research was provided by:
Tokai University, Isehara Campus
- License Information
-
More Information
Article History
Received: 20 May 2025
Accepted: 23 August 2025
First Online: 3 September 2025
Declarations
:
: Kondo M and Okino S declare there are no conflicts of interest. Ms. Nakaya reports grants from 2024 Tokai University School of Medicine Research Aid, grants from 2023 Foundation for Promotion of Cancer Research in Japan—all unrelated to the submitted work. Dr. Yamasato reports grants from Grants-in-Aid for Scientific Research—all unrelated to the submitted work. Dr. Kitano reports grants and personal fees from Shiseido Co., Ltd., personal fees from Eisai Co., Ltd., personal fees from Dai-ichi Sankyo Co., Ltd., personal fees from Chugai Pharma Co., Ltd., personal fees from Pfizer Japan Inc., personal fees from Eli Lilly and Company, and personal fees from AstraZeneca KK Co., Ltd. — all unrelated to the submitted work. Dr. Tsuda reports personal compensation from Daiichi Sankyo Co., Ltd., MSD K.K., Shionogi & Co., Ltd., and Ono Pharmaceutical Co., Ltd.—all unrelated to the submitted work. Dr. Tokuhara reports personal fees from Otsuka Pharmaceutical Factory, Inc., personal fees from Eisai Co., Ltd., and personal fees from Specialist Doctors Inc.—all unrelated to the submitted work. Dr. Yamamoto reports grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants and personal fees from Shionogi & Co., Ltd, grants and personal fees from Eisai Co., Ltd., personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from Sumitomo Dainippon Pharma Co., Ltd., personal fees from Meiji Seika Pharma Co., Ltd., personal fees from Pfizer Japan Inc., personal fees from Eli Lilly and Company, personal fees from EA Pharma Co., Ltd., personal fees from Merck Sharp & Dohme, personal fees from Viatris Inc., personal fees from Astellas Pharma Co., Ltd., grants from Grants-in-Aid for Scientific Research (C), grants from medical corporation, Tanzawa hospital, grants from medical corporation, Seishinkai, grants from medical corporation, Kishikai, grants from medical corporation, Kensuikai, grants from medical corporation, Seikikai, grants from medical corporation, Kyogetsukai, grants from medical corporation, Aokisuejiroukinenkai, grants from Social welfare corporation and Social Business department of Houanji—all unrelated to the submitted work.
: The study was approved by the Research Ethics Committee of the Tokai School of Medicine (approval number: 20R245) and the Research Ethics Committee of St. Luke’s International Hospital (approval number: 21R006).
